Guangzhou Kingmed Diagnostics Hits Day Low Amid Price Pressure at CNY 28.60

Guangzhou Kingmed Diagnostics Group Co., Ltd. experienced a significant decline today, with the stock dropping by 5.06% to reach an intraday low of CNY 28.60. This performance stands in contrast to the China Shanghai Composite, which fell by only 1.26% on the same day. Over the past week, the stock has decreased by 5.9%, and its one-month performance shows a decline of 9.89%. In terms of longer-term performance, Guangzhou Kingmed has faced considerable challenges, with a year-to-date increase of just 1.2%, while the China Shanghai Composite has gained 2.85%. The stock has underperformed significantly over the past three years, with a staggering decline of 64.46%, and a five-year drop of 79.09%. Financial metrics indicate ongoing difficulties, as the company reported a net sales decline of 18.69% and a net profit loss of CNY 51.82 million, reflecting a 146.08% decrease. The return on capital employed (ROCE) stands at a low -7.57%, highlighting the company's struggles in maintaining profitability. Overall, the stock's performance continues to reflect a challenging environment within the pharmaceuticals and biotechnology sector.